Doctors' perceptions of clinical trials 'influenced by funding sources'
Doctors tend to be biased against industry-funded clinical trials, a study has found.
Doctors are less likely to trust the findings of a clinical trial if it was funded by a pharmaceutical company, new research has found.
Even in cases where a trial was conducted rigorously and to a high standard, doctors were found to take a dim view of the conclusions if they learnt it was industry-funded.
The study was conducted by researchers at Harvard Medical School in Boston and involved more than 500 doctors who were shown hypothetical abstracts and questioned on the evidence presented.
Doctors tended to downgrade the rigour of a trial, their confidence in the results and their willingness to prescribe the drug in question if it was funded by a pharmaceutical company.
Publishing their findings in the New England Journal of Medicine, the study authors concluded that industry sponsorship "negatively influences [doctors'] perception of methodologic quality and reduces their willingness to believe and act on trial findings, independently of the trial's quality".
They added that this could influence the translation of clinical research into practice.
Writing in an accompanying editorial, Dr Jeffrey Drazen, the journal's editor-in-chief, argued that a trial's validity should ride on its design, the quality of data collection and analytic processes, and the fairness of the reporting.
"Ideally, these factors - not the funding source - should be the criteria for deciding the clinical utility," he added.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance